NCT03702777View on ClinicalTrials.gov

A Study of ASP8302 in Participants With Underactive Bladder

PHASE2CompletedINTERVENTIONAL

Enrollment

135

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

April 28, 2020

Study Completion Date

April 28, 2020

Conditions

Underactive Bladder

Interventions

DRUG

ASP8302

Oral Capsule

DRUG

Placebo

Oral Capsule

Trial Locations (29)

Unknown

Site DE49001, Duisburg

Site DE49002, Duisburg

Site DE49004, Gronau

Site DE49003, Mönchengladbach

Site JP81009, Nagoya

Site JP81008, Ōbu

Site JP81007, Yoshida-gun

Site JP81006, Asahikawa

Site JP81005, Sapporo

Site JP81015, Sapporo

Site JP81002, Kobe

Site JP81012, Kurashiki

Site JP81011, Sayama

Site JP81001, Shimotsuga-gun

Site JP81003, Fukuoka

Site JP81004, Kumamoto

Site JP81010, Saga

Site JP81013, Shizuoka

Site NL31003, Eindhoven

Site NL31002, Maastricht

Site NL31001, Rotterdam

Site PL48004, Mysłowice

Site PL48003, Piaseczno

Site PL48002, Szczecin

Site PL48001, Warsaw

Site SK42103, Košice

Site SK42101, Nitra

Site SK42102, Trenčín

Site UK44002, Bristol

All Listed Sponsors

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT03702777 - A Study of ASP8302 in Participants With Underactive Bladder | Biotech Hunter | Biotech Hunter